테고사이언스
191420KOSDAQ기초 의약물질 제조업38.0 / 100
Reference Date: 2026-07-24
Company InformationBased on 2025 Annual Report
Business Overview
Tegos Science specializes in developing and producing cell therapy products using advanced cell culture technology, alongside offering contract manufacturing, consulting, and quality management services. The company has commercialized a 3D cultured skin model, NeoDerm®, for animal alternative testing and drug screening. The global cell therapy market is projected to grow from $4.2 billion in 2023 to $7.8 billion by 2028, with Tegos holding three approved cell therapy products in South Korea, including treatments for burns, diabetic foot ulcers, and wrinkle improvement.
Number of Employees
40people
Average Salary
48.0M KRW
Score Calculation Basis
Detailed Financial Score
In line with industry avg
2.3x industry avg (excellent)
7.2x industry avg (risky)
Avg ▼12.6% (2-year basis)
Avg ▼93.1% (2-year basis)
Avg ROE -4.0% (declining, 3yr)
Detailed News Sentiment
- Neutral흡수율 '625%' 논란에 화들짝…에이피알 "객관적 시험 수치"
에이피알이 '625% 흡수율' 홍보 논란에 대해 객관적인 시험 결과를 제시했으나, 관련 이슈는 해당 기업의 직접적인 재무 영향보다는 브랜드 이미지에 초점을 맞추고 있어 중립적 평가.
Detailed Momentum
Near 52w low (0%, downtrend)
1m -10.00% (falling)
Volume decreasing
Detailed Disclosure
- Neutral[기재정정]사업보고서 (2025.12)2026-06-25
